β-catenin mediates tumor-induced immunosuppression by inhibiting cross-priming of CD8⁺ T cells.
Xinjun Liang,Chunmei Fu,Weiguo Cui,Julia L. Ober-Blöbaum,Julia L. Ober-Blöbaum,Sonja Zahner,Protul Shrikant,Björn E. Clausen,Björn E. Clausen,Richard A. Flavell,Ira Mellman,Aimin Jiang +11 more
Reads0
Chats0
TLDR
Testing the hypothesis that β‐catenin in DCs mediates tumor‐induced suppression of CD8+ T cell immunity by inhibiting the ability of DCs in cross‐priming found that it represents a new and potentially general mechanism that tumors employ to achieve immunosuppression.Abstract:
Whereas CD8⁺ T cells are essential for anti-tumor immunity, tumors often evade CD8⁺ T cell surveillance by immunosuppression As the initiators of antigen-specific immune responses, DCs are likely to play a central role in regulating the balance between immunity and tolerance to tumor antigens and are specialized in their ability to cross-present exogenous tumor antigens on MHC class I molecules to initiate CD8⁺ T cell immunity However, it remains unclear whether and how tumors modulate DC functions to suppress CD8⁺ T cell responses We have shown previously that β-catenin signaling in DCs promotes DC-mediated CD8⁺ T cell tolerance Here, we tested the hypothesis that β-catenin in DCs mediates tumor-induced suppression of CD8⁺ T cell immunity by inhibiting the ability of DCs in cross-priming β-Catenin was activated in DCs by multiple tumors in vivo and in vitro B16 melanoma-bearing mice, when vaccinated with DC-targeting anti-DEC-205 mAb fused with tumor antigens, exhibited dampened CD8⁺ immunity, similar to DC-β-catenin(active) mice DCs from DC-β-catenin(active) and tumor-bearing mice were deficient in cross-priming, and antigen-specific CD8⁺ T cells primed in these mice resulted in dampened CD8⁺ memory responses Importantly, DC-β-catenin⁻/⁻ mice completely abrogate tumor-mediated inhibition of cross-priming, suggesting that tumor-induced inhibition of cross-priming is dependent on β-catenin Finally, enhancing cross-priming at the priming or recall phase rescued β-catenin-suppressed CD8⁺ immunity in DC-β-catenin(active) and tumor-bearing mice Thus, β-catenin-mediated inhibition of cross-priming represents a new and potentially general mechanism that tumors employ to achieve immunosuppressionread more
Citations
More filters
Journal ArticleDOI
Dendritic cells in cancer immunology and immunotherapy.
Stefanie K. Wculek,Francisco J. Cueto,Adriana M. Mujal,Ignacio Melero,Matthew F. Krummel,David Sancho +5 more
TL;DR: How different DC subsets influence immunity and tolerance in cancer settings is outlined and the implications for both established cancer treatments and novel immunotherapy strategies are discussed.
Journal ArticleDOI
CD4+ T cell help is required for the formation of a cytolytic CD8+ T cell subset that protects against chronic infection and cancer
Ryan Zander,David M. Schauder,Gang Xin,Christine Nguyen,Xiaopeng Wu,Allan J. Zajac,Weiguo Cui,Weiguo Cui +7 more
TL;DR: The findings uncovered the formation of a CX3CR1-expressing CD8+ T cell subset that exhibited potent cytolytic function and was required for viral control and have implications toward optimizing the generation of protective CD8- T cells in immunotherapy.
Journal ArticleDOI
Dendritic Cells and CD8 T Cell Immunity in Tumor Microenvironment.
Chunmei Fu,Aimin Jiang +1 more
TL;DR: Recent advances in anti-tumor CD8 T cell cross-priming by CD103+ cDC1s in TME are discussed, and perspective on future directions including therapeutic applications and memory CD 8 T cell responses is shared.
Journal ArticleDOI
Dendritic cell-targeted vaccines.
Lillian B. Cohn,Lélia Delamarre +1 more
TL;DR: In this article, the authors discuss considerations relevant to the design of such vaccines: the existence of DC subsets with specialized functions, the impact of the antigen intracellular trafficking on cross-presentation, and the influence of maturation signals received by DCs on the outcome of the immune response.
Journal ArticleDOI
Dendritic cells as gatekeepers of tolerance
TL;DR: Over the past decade, accumulating data indicate that DC critically contribute to Treg differentiation and homeostasis.
References
More filters
Journal ArticleDOI
Wnt signalling in stem cells and cancer
Tannishtha Reya,Hans Clevers +1 more
TL;DR: Insights gained from understanding how the Wnt pathway is integrally involved in both stem cell and cancer cell maintenance and growth in the intestinal, epidermal and haematopoietic systems may serve as a paradigm for understanding the dual nature of self-renewal signals.
Journal ArticleDOI
Cancer immunotherapy comes of age
TL;DR: In the context of advances in the understanding of how tolerance, immunity and immunosuppression regulate antitumour immune responses, these successes suggest that active immunotherapy represents a path to obtain a durable and long-lasting response in cancer patients.
Journal ArticleDOI
Tolerogenic dendritic cells.
TL;DR: It is suggested that several clinical situations, including autoimmunity and certain infectious diseases, can be influenced by the antigen-specific tolerogenic role of DCs.
Journal ArticleDOI
Taking dendritic cells into medicine
TL;DR: Some medical implications of DC biology that account for illness and provide opportunities for prevention and therapy are presented.
Journal ArticleDOI
Dendritic Cells Induce Peripheral T Cell Unresponsiveness under Steady State Conditions in Vivo
Daniel Hawiger,Kayo Inaba,Kayo Inaba,Yair Dorsett,Ming Guo,Karsten Mahnke,Miguel Rivera,Jeffrey V. Ravetch,Ralph M. Steinman,Michel C. Nussenzweig,Michel C. Nussenzweig +10 more
TL;DR: An antigen delivery system targeting these specialized antigen presenting cells in vivo using a monoclonal antibody to a DC-restricted endocytic receptor is devised, which concludes that in the absence of additional stimuli DCs induce transient antigen-specific T cell activation followed by T cell deletion and unresponsiveness.
Related Papers (5)
Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity
Tumor-Residing Batf3 Dendritic Cells Are Required for Effector T Cell Trafficking and Adoptive T Cell Therapy.
Expansion and Activation of CD103(+) Dendritic Cell Progenitors at the Tumor Site Enhances Tumor Responses to Therapeutic PD-L1 and BRAF Inhibition.
Hélène Salmon,Juliana Idoyaga,Adeeb Rahman,Marylene Leboeuf,Romain Remark,Stefan Jordan,Maria Casanova-Acebes,Makhzuna Khudoynazarova,Judith Agudo,Navpreet Tung,Svetoslav Chakarov,Christina Rivera,Brandon Hogstad,Marcus Bosenberg,Daigo Hashimoto,Sacha Gnjatic,Nina Bhardwaj,Anna Karolina Palucka,Brian D. Brown,Joshua Brody,Florent Ginhoux,Miriam Merad +21 more